MICRO-X LIMITED (MX1)
Share Price Analysis and Chart
Enter the company code or Name for stock analysis:
MX1 - MICRO-X LIMITED
FNArena Sector :
Medical Equipment & Devices
Year End: June
GICS Industry Group : Health Care Equipment & Services
Debt/EBITDA: -0.32
Index:
FNArena Sector : Medical Equipment & Devices
Year End: June
GICS Industry Group : Health Care Equipment & Services
Debt/EBITDA: -0.32
LAST PRICE | CHANGE +/- | CHANGE % | VOLUME |
---|---|---|---|
$0.09
14 May |
0.000 OPEN $0.09 |
0.000 HIGH $0.09 |
282,837 LOW $0.09 |
TARGET | |||||
|
OTHER COMPANIES IN THE SAME SECTOR | |||
4DX . AT1 . BRN . CAT . CBL . CGS . CMP . COH . CSX . CU6 . CYC . EBR . EMV . EYE . FPH . IDX . IME . IMR . IPD . LDX . NAN . ONE . PCK . PEB . PGC . PME . RMD . SOM . TRJ . UBI . VHT . VTI . |
FNARENA'S MARKET CONSENSUS FORECASTS
Title | FY22 Actual |
FY23 Actual |
FY24 Forecast |
FY25 Forecast |
---|---|---|---|---|
EPS (cps) | xxx | N/A | - 1.7 | xxx |
DPS (cps) | xxx | N/A | 0.0 | xxx |
EPS Growth | xxx | N/A | N/A | xxx |
DPS Growth | xxx | N/A | N/A | xxx |
PE Ratio | xxx | N/A | N/A | xxx |
Dividend Yield | xxx | N/A | 0.0% | xxx |
Div Pay Ratio(%) | xxx | N/A | N/A | xxx |
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2024 FactSet UK Limited. All rights reserved
Title | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
EPS Basic | xxx | xxx | xxx | xxx | xxx | -2.2 |
DPS All | xxx | xxx | xxx | xxx | xxx | 0.0 |
Sales/Revenue | xxx | xxx | xxx | xxx | xxx | 15.0 M |
Book Value Per Share | xxx | xxx | xxx | xxx | xxx | 3.3 |
Net Operating Cash Flow | xxx | xxx | xxx | xxx | xxx | -11.0 M |
Net Profit Margin | xxx | xxx | xxx | xxx | xxx | -71.67 % |
EPS Basic
DPS All
Sales/Revenue
Book Value Per Share
Net Operating Cash Flow
Net Profit Margin
Title | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Return on Capital Employed | xxx | xxx | xxx | xxx | xxx | -59.17 % |
Return on Invested Capital | xxx | xxx | xxx | xxx | xxx | -47.65 % |
Return on Assets | xxx | xxx | xxx | xxx | xxx | -34.93 % |
Return on Equity | xxx | xxx | xxx | xxx | xxx | -59.17 % |
Return on Total Capital | xxx | xxx | xxx | xxx | xxx | -70.10 % |
Free Cash Flow ex dividends | xxx | xxx | xxx | xxx | xxx | -11.8 M |
Return on Capital Employed
Return on Invested Capital
Return on Assets
Return on Equity
Return on Total Capital
Free Cash Flow ex dividends
Title | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Short-Term Debt | xxx | xxx | xxx | xxx | xxx | 1 M |
Long Term Debt | xxx | xxx | xxx | xxx | xxx | 4 M |
Total Debt | xxx | xxx | xxx | xxx | xxx | 5 M |
Goodwill - Gross | xxx | xxx | xxx | xxx | xxx | - |
Cash & Equivalents - Generic | xxx | xxx | xxx | xxx | xxx | 5 M |
Price To Book Value | xxx | xxx | xxx | xxx | xxx | 3.60 |
Short-Term Debt
Long Term Debt
Total Debt
Goodwill - Gross
Cash & Equivalents - Generic
Price To Book Value
Title | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Capex | xxx | xxx | xxx | xxx | xxx | 0.8 M |
Capex % of Sales | xxx | xxx | xxx | xxx | xxx | 5.19 % |
Cost of Goods Sold | xxx | xxx | xxx | xxx | xxx | 22 M |
Selling, General & Admin. Exp & Other | xxx | xxx | xxx | xxx | xxx | 9 M |
Research & Development | xxx | xxx | xxx | xxx | xxx | - |
Investments - Total | xxx | xxx | xxx | xxx | xxx | - |
Capex
Capex % of Sales
Cost of Goods Sold
Selling, General & Admin. Exp & Other
Research & Development
Investments - Total
EXPERT VIEWS
Display All Commentary
Sentiment Indicator
No. Of Recommendations
MX1 STOCK CHART
FNArena News on MX1
1 |
FNArena Corporate Results Monitor – 29-02-2024Feb 29 2024 - Australia |
2 |
Dr Boreham’s Crucible: Argenica TherapeuticsSep 28 2023 - Small Caps |
3 |
FNArena Corporate Results Monitor – 31-08-2023Aug 31 2023 - Australia |
4 |
FNArena Corporate Results Monitor – 28-02-2023Feb 28 2023 - Australia |
5 |
FNArena Corporate Results Monitor – 31-08-2022Aug 31 2022 - Australia |
Latest Medical Equipment & Devices News
1 |
ResMed Silences The DoubtersApr 29 2024 - Australia |
2 |
Dr Boreham’s Crucible: 4D MedicalApr 23 2024 - Small Caps |
3 |
Uptrend Resumed For ResMedMar 19 2024 - Technicals |
4 |
Dr Boreham’s Crucible: CochlearFeb 28 2024 - Australia |
5 |
Rudi Interviewed: Ongoing Potential In Technology & GrowthFeb 19 2024 - Rudi's View |
6 |
Dr Boreham’s Crucible: ArtryaFeb 15 2024 - Small Caps |
7 |
ResMed Recovery Turns Into Hollywood ScriptJan 31 2024 - Australia |
8 |
ResMed Makes A ComebackJan 29 2024 - Australia |
9 |
ResMed: The Recovery Has BegunJan 23 2024 - Technicals |
10 |
Dr Boreham’s Crucible: Pro MedicusOct 23 2023 - Australia |